Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | COMT | P21964 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388796 | 0.88 | L3MBTL1 (0.58) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL15116255 | 0.84 | KDM4E (0.74) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL17962271 | 0.83 | KDM4E (1.00) | KDM4ECOMTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1102244 | 0.82 | KDM4E (0.70) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL17960049 | 0.81 | COMT (1.00) | KDM4ECOMTSMN1; SMN2 | |
| SCHEMBL13820759 | 0.81 | KDM4E (0.69) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL17960031 | 0.76 | COMT (0.60) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL9397254 | 0.74 | ALDH1A1 (0.67) | KDM4ECOMTLMNAHTTALDH1A1 | |
| SCHEMBL17962367 | 0.73 | COMT (1.00) | KDM4ECOMTLMNAHTTSMN1; SMN2 | |
| SCHEMBL17962417 | 0.73 | COMT (0.78) | KDM4ECOMTLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885COMT 3905/4885LMNA 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.